# A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

> **NCT01959594** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 3 mg PF-06412562
- **DRUG:** 10 mg PF-06412562
- **DRUG:** 25 mg PF-06412562
- **DRUG:** PF-06412562 TBD mg
- **DRUG:** PF-06412562 TBD mg

## Key facts

- **NCT ID:** NCT01959594
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959594, "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01959594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*